ATE106449T1 - Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen. - Google Patents

Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen.

Info

Publication number
ATE106449T1
ATE106449T1 AT90911196T AT90911196T ATE106449T1 AT E106449 T1 ATE106449 T1 AT E106449T1 AT 90911196 T AT90911196 T AT 90911196T AT 90911196 T AT90911196 T AT 90911196T AT E106449 T1 ATE106449 T1 AT E106449T1
Authority
AT
Austria
Prior art keywords
amino acid
protein
terminal
type
regulator
Prior art date
Application number
AT90911196T
Other languages
English (en)
Inventor
Rohan T Baker
David K Gonda
Alexander Varshavsky
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Application granted granted Critical
Publication of ATE106449T1 publication Critical patent/ATE106449T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67General methods for enhancing the expression
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/24Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C12N9/2471Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y302/00Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01023Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/61Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/95Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
AT90911196T 1989-06-30 1990-06-27 Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen. ATE106449T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37382589A 1989-06-30 1989-06-30

Publications (1)

Publication Number Publication Date
ATE106449T1 true ATE106449T1 (de) 1994-06-15

Family

ID=23474039

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90911196T ATE106449T1 (de) 1989-06-30 1990-06-27 Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen.

Country Status (10)

Country Link
US (1) US5766927A (de)
EP (1) EP0479912B1 (de)
JP (1) JP2904921B2 (de)
AT (1) ATE106449T1 (de)
AU (1) AU5963290A (de)
CA (1) CA2063400C (de)
DE (1) DE69009476T2 (de)
DK (1) DK0479912T3 (de)
ES (1) ES2054365T3 (de)
WO (1) WO1991000356A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861312A (en) * 1997-12-02 1999-01-19 California Institute Of Technology Nucleic acid encoding mammalian UBR1
WO2000042185A1 (en) * 1999-01-11 2000-07-20 Mindset Biopharmaceuticals (Usa), Inc. Methods for regulating the stability of recombinant proteins and products useful therein
US6306663B1 (en) * 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
WO2000050089A2 (en) * 1999-02-26 2000-08-31 Mindset Biopharmaceuticals (Usa) Ltd. Regulation of the stability of recombinant proteins and antiboodies
US7262005B1 (en) 2000-02-04 2007-08-28 Aurora Biosciences Corporation Methods of protein destabilization and uses thereof
US8343502B2 (en) 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
BR0316758A (pt) 2002-12-16 2005-10-25 Globeimmune Inc Vacinas baseadas em levedura como imunoterapia
EP2066697A2 (de) * 2006-09-26 2009-06-10 Massachusetts Institute of Technology Modifizierte selbstanordnende peptide
US8173792B2 (en) 2007-02-09 2012-05-08 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells using synthetic small molecules
US8530636B2 (en) 2008-05-07 2013-09-10 The Board Of Trustees Of The Leland Stanford Junior University Method for regulating protein function in cells in vivo using synthetic small molecules
WO2011088421A2 (en) * 2010-01-15 2011-07-21 California Institute Of Technology Discovery and applications of the proteolytic function of n-terminal acetylation of cellular proteins
EP3443001A4 (de) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. Regulierte bioschaltkreissysteme
KR20230013034A (ko) 2020-04-20 2023-01-26 베스타론 코포레이션 해충 제어를 위한 단백분해 안정형 u1-아가톡신-ta1b 변이체 폴리펩티드
MX2022013415A (es) 2020-05-01 2022-11-14 Vestaron Corp Combinaciones de insecticidas.
WO2022212777A2 (en) 2021-04-01 2022-10-06 Vestaron Corporation Av3 mutant polypeptides for pest control
WO2023097309A1 (en) 2021-11-29 2023-06-01 Ironwood Pharmaceuticals, Inc. Pharmaceutical compositions for the treatment of visceral pain
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method
WO2023225555A1 (en) 2022-05-18 2023-11-23 Vestaron Corporation Pesticidal actx peptide variants
WO2023245100A1 (en) 2022-06-17 2023-12-21 Vestaron Corporation Antimicrobial ncr13 variant peptides
WO2024026406A2 (en) 2022-07-29 2024-02-01 Vestaron Corporation Next Generation ACTX Peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512979A (en) * 1981-03-23 1985-04-23 Merck & Co., Inc. Dipeptides containing thialysine and related amino acids as antihypertensives
US4514391A (en) * 1983-07-21 1985-04-30 E. R. Squibb & Sons, Inc. Hydroxy substituted peptide compounds
US4551445A (en) * 1983-10-14 1985-11-05 The Medical College Of Ohio Derivatives of arginine vasopressin antagonists
US5132213A (en) * 1986-10-02 1992-07-21 Massachusetts Institute Of Technology Method for producing proteins and polypeptides using ubiquitin fusions
DE3752372T2 (de) * 1986-10-02 2004-06-24 Massachusetts Institute Of Technology, Cambridge Verfahren zur regulierung der metabolischen stabilität von proteinen
US5108919A (en) * 1988-06-24 1992-04-28 Genentech, Inc. Dna sequences encoding yeast ubiquitin hydrolase
CH680013A5 (de) * 1988-09-19 1992-05-29 Mathias Och

Also Published As

Publication number Publication date
DE69009476T2 (de) 1994-12-22
JPH04506298A (ja) 1992-11-05
EP0479912A1 (de) 1992-04-15
DK0479912T3 (da) 1994-10-10
WO1991000356A1 (en) 1991-01-10
CA2063400A1 (en) 1990-12-31
CA2063400C (en) 1997-07-15
AU5963290A (en) 1991-01-17
DE69009476D1 (de) 1994-07-07
ES2054365T3 (es) 1994-08-01
EP0479912B1 (de) 1994-06-01
US5766927A (en) 1998-06-16
JP2904921B2 (ja) 1999-06-14

Similar Documents

Publication Publication Date Title
ATE106449T1 (de) Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen.
Reed et al. Sequence of residues 400--403 of bovine serum albumin.
Finley et al. Ubiquitination
Gregory et al. The primary structure of human urogastrone
ES2063350T3 (es) Nuevas proteinas con efecto inhibidor del tnf y su produccion.
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
FI842166A0 (fi) Bukspottskoertelns grf hos maenniskan.
ATE171712T1 (de) Neuartiger menschlicher proteaseinhibitor vom kunitz-typ und entsprechende varianten
DE3486154D1 (de) Cardiodilatin, ein neues peptidhormon und verfahren zu seiner herstellung.
DE3261304D1 (en) Retro-inverso analogues of c-terminal penta and hexapeptides of substance p.
Ramage et al. Solid phase peptide synthesis of ubiquitin
ABEL et al. Structural differences in the hinge region of human gamma A myeloma proteins of different subclasses
DK0446315T3 (da) Fremgangsmåde til fremstilling af PAI-2
Brandt et al. Complete amino acid sequence of the N-terminal extension of calf skin type III procollagen
Costantino et al. Atypical pattern of utilization of amino acids for mitochondrial protein synthesis in HeLa cells
Hackeng et al. Chemical synthesis of human protein S thrombin‐sensitive module and first epidermal growth factor module
AU2676399A (en) Novel cystine knot protein and materials and methods for making it
NO20016341L (no) Inhibitorer for integrinet <alfa>v<beta>6
Marquis et al. Stoichiometry and structure of a complex of acidic ribosomal proteins
Liebisch et al. Isolation and structure of a C-terminally amidated nonopioid peptide, amidorphin-(8-26), from bovine striatum: a major product of proenkephalin in brain but not in adrenal medulla.
GEN Maria Kehl and Agnes Henschen
DE60326726D1 (de) Peptide mit affinität für ein phospholipid und deren verwendung
RU94036002A (ru) Ингибитор протеазы, днк, вектор, клетка, способ получения ингибитора, фармацевтическая композиция
RU94036770A (ru) Домен ингибитора протеазы, днк, вектор, клетка, способ получения домена, фармацевтическая композиция, применение домена
TH54460A3 (th) สารผสมฟลินท์ (flint) และการใช้ของสารผสม

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee